Status:
COMPLETED
DAW1033B2 in Obstructive Sleep Apnea
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Obstructive Sleep Apnea (OSA)
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
PHASE2
Brief Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep ...
Eligibility Criteria
Inclusion
- Inclusion Criterion:
- OSA: AHI \> 15
- Exclusion Criteria:
- Any medical condition other than well controlled hypertension, diabetes, hyperlipidemia
- Any medication known to influence breathing, sleep/arousal or muscle physiology.
- Claustrophobia.
- Inability to sleep supine.
- Allergy to lidocaine, Oxymetazoline HCl, DAW1033D.
- Individuals with underlying cardiac disease, such as arrhythmias.
- Individuals taking psychiatric medications, or any of the studied medications for medical care.
- History of seizures
- For women: Pregnancy.
- History of panic disorder / hyperventilation syndrome / Attention deficit-hyperactivity disorder (ADHD) / autism
Exclusion
Key Trial Info
Start Date :
September 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 20 2020
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT03426631
Start Date
September 15 2017
End Date
January 20 2020
Last Update
February 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sleep Disorders Research Program Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115